Cardiology
HCM Risk-SCD for Hypertrophic Cardiomyopathy
Estimates 5-year risk of sudden cardiac death (SCD) in hypertrophic cardiomyopathy to guide ICD implantation (ESC 2014 model).
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Lidocaine IV (Cardiac Arrhythmia) · Antiarrhythmic
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Mavacamten · Cardiac myosin inhibitor
- Prednisolone (Sudden Sensorineural Hearing Loss) · Corticosteroid (systemic — SSNHL treatment)
- Digoxin · Cardiac Glycoside
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.